Table 3.
Univariate analysis for the factors associated with posttransplant metabolic syndrome
| Variable | OR (95%CI) | P value | 
| Age | 1.26 (0.48-3.31) | 0.642 | 
| Male | 1.25 (0.34-4.64) | 0.735 | 
| Smoking | 1.33 (0.45-3.92) | 0.605 | 
| Alcohol | 2.44 (0.83-7.13) | 0.104 | 
| HBV | 0.92 (0.34-2.47) | 0.865 | 
| HCV | 0.43 (2.25-13.6) | 0.408 | 
| BMI | 7.69 (1.75-33.8) | 0.007 | 
| Pre-LT diabetes mellitus | 2.19 (0.64-7.55) | 0.214 | 
| Pre-LT hypertension | 1.62 (0.17-15.3) | 0.674 | 
| Pre-LT dyslipidemia | 2.17 (0.27-17.5) | 0.469 | 
| Donor age | 2.42 (0.67-8.74) | 0.178 | 
| Donor BMI | 1.91 (0.37-9.90) | 0.443 | 
| WIT | 1.21 (1.04-1.41) | 0.014 | 
| CIT | 0.95 (0.69-1.31) | 0.741 | 
| Steroid-free protocol for HCC | 0.35 (0.10-1.24) | 0.065 | 
| Tacrolimus use ≥ 24 mo | 1.77 (0.39-4.01) | 0.591 | 
| Cyclosporine use ≥ 24 mo | 1.30 (0.50-3.40) | 0.591 | 
| MMF use ≥ 24 mo | 1.05 (0.39-2.83) | 0.920 | 
| Acute graft rejection | 1.69 (0.43-6.61) | 0.450 | 
| Biliary complication | 0.48 (0.17-2.28) | 0.467 | 
| Acute kidney injury | 4.72 (1.60-14.0) | 0.005 | 
| Hyperuricemia | 6.95 (2.54-19.0) | < 0.001 | 
OR: Odds ratio; CI: Confidence interval; HBV: Hepatitis B virus; HCV: Hepatitis C virus; BMI, Body mass index; WIT: Warm ischemia time; CIT; Cold ischemia time; LT: Liver transplantation; HCC: Hepatocellular carcinoma; MMF: Mycophenolate mofetil.